Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.100 AlteredExpression group BEFREE THSD7A was found to be expressed in a variety of malignant tumors. 31443644 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.100 Biomarker group BEFREE In two patients, cancer was detected at the time of renal biopsy (small-cell carcinoma of the lung and prostatic adenocarcinoma with neuroendocrine differentiation).Both tumours were negative for THSD7A. 30868298 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.100 Biomarker group BEFREE THSD7A staining in cancer tissues was also assessed in 9 of the 36 patients. 31243053 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.100 Biomarker group BEFREE Screening for malignancy is particularly advised in THSD7A-mediated membranous nephropathy. 31045661 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.100 GeneticVariation group BEFREE However, there are few case reports on THSD7A-associated MN with malignancy, and details of its characteristics have not been clarified thoroughly. 30727973 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.100 Biomarker group BEFREE The presence of anti-THSD7A antibodies is associated with increased risk of malignancy. 29511687 2018
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.100 Biomarker group BEFREE A notable phenomenon is the high rate of cancer (reported to be as high as 20%) in patients with THSD7A-associated MN. 29079545 2018
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.100 Biomarker group BEFREE We aimed to systematically evaluate the prevalence of THSD7A in IMN patients and malignancies in THSD7A-positive patients. 29623759 2018
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.100 Biomarker group BEFREE In order to better define the underlying immunologic processes, we systematically analyzed circulating antigen-specific IgG subclasses in the serum of 76 patients with PLA<sub>2</sub>R1-associated MN and 41 patients with THSD7A-associated MN in relationship to concurrent malignancy and disease outcome. 30619370 2018
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.100 AlteredExpression group BEFREE THSD7A expression in human cancer. 28035718 2017
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.100 GeneticVariation group BEFREE Although similar information is not yet available for THSD7A-associated MN, this form of MN may have a unique association with malignancy. 28674044 2017
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.100 Biomarker group BEFREE Patients with THSD7A-associated MN differ in their clinical characteristics from patients with PLA<sub>2</sub>R1-associated MN, and more intensive screening for the presence of malignancies may be warranted in those with THSD7A-associated MN. 27436855 2017